{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:27:13Z","timestamp":1771036033109,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"International, Clinical Operational and Health Services Research Training Award (ICOHRTA)"},{"name":"African Programme for Training in HIV\/TB Research Fogarty International Center","award":["NIH U2R TW006878"],"award-info":[{"award-number":["NIH U2R TW006878"]}]},{"name":"Stanford-SPARK"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jviromet.2016.11.010","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T22:30:55Z","timestamp":1480113055000},"page":"151-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing"],"prefix":"10.1016","volume":"243","author":[{"given":"Benjamin","family":"Chimukangara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavini","family":"Varyani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tinei","family":"Shamu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junior","family":"Mutsvangwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justen","family":"Manasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cleophas","family":"Chimbetete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruedi","family":"Luethy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2016.11.010_bib0005","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/01.inf.0000243211.36690.d5","article-title":"Diminished selection for thymidine-analog mutations associated with the presence of M184 V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy","volume":"25","author":"Averbuch","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4172\/2155-6113.1000141","article-title":"Comparing peripheral blood mononuclear cell DNA and circulating plasma viral RNA pol genotypes of subtype C HIV-1","volume":"3","author":"Banks","year":"2012","journal-title":"J. AIDS Clin. Res."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0015","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1097\/QAD.0b013e328313bf87","article-title":"Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa","volume":"22","author":"Barth","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0020","unstructured":"Bayer HIV-1 TRUGENE Genotyping Method. Internet. Available: https:\/\/www.hanc.info\/labs\/labresources\/procedures\/ACTGIMPAACTLabManual\/BayerTruGeneHIV-1Genotyping.pdf (Accessed: October 2016)."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350801302S04","article-title":"Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment","author":"Bennett","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0030","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","article-title":"Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa","volume":"71","author":"Boender","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0035","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.37.10.2231","article-title":"High-level resistance to enantiomeric 2\u2019-deoxy-3\u2019-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase","volume":"37","author":"Boucher","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0040","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1128\/JVI.76.7.3248-3256.2002","article-title":"The M184V mutation reduces the selective excision of zidovudine 5\u2019-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1","volume":"76","author":"Boyer","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1468-1293.2008.00607.x","article-title":"Genotypic antiretroviral drug resistance testing at low viral loads in the UK","volume":"9","author":"Cane","year":"2008","journal-title":"HIV Med."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0050","doi-asserted-by":"crossref","unstructured":"Chaturbhuj D.N., Nirmalkar A.P., Paranjape R.S., Tripathy S.P., Evaluation of a Cost Effective In-House Method for HIV-1 Drug Resistance Genotyping Using Plasma Samples. Wainberg M, editor. PLoS One. San Francisco, USA: Public Library of Science; 2014;9: e87441. 10.1371\/journal.pone.008744.","DOI":"10.1371\/journal.pone.0087441"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/1570162X12666141017100733","article-title":"Drug resistance mutations from whole blood proviral DNA among patients on antiretroviral drugs in Zimbabwe","volume":"12","author":"Chimukangara","year":"2014","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0060","doi-asserted-by":"crossref","first-page":"e0117430","DOI":"10.1371\/journal.pone.0117430","article-title":"HIV drug resistance mutations in proviral DNA from a community treatment program","volume":"10","author":"Derache","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0065","doi-asserted-by":"crossref","unstructured":"Dybul M., Fauci A.S., Bartlett J.G., Kaplan J.E., Pau A.K., Mark Dybul John G. Bartlett, Jonathan E. Kaplan, Alice K. Pau, 2002. ASF. Guidelines for Using Antiretroviral Agents Among HIV-Infected Adults and Adolescents. In: Recommendations of the Panel on Clinical Practices for Treatment of HIV. pp. 381\u2013433.","DOI":"10.7326\/0003-4819-137-5_Part_2-200209031-00001"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0070","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32833a097b","article-title":"Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa","volume":"24","author":"El-Khatib","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0075","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1128\/JVI.74.8.3579-3585.2000","article-title":"The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis","volume":"74","author":"G\u00f6tte","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0080","unstructured":"Global Aids Response Report. National AIDS Council, Zimbabwe, 2015."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0085","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cid\/ciu019","article-title":"Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals","volume":"58","author":"Gonzalez-Serna","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0090","doi-asserted-by":"crossref","unstructured":"Hosseinipour M.C., Gupta R.K., Van Zyl G., Eron J.J., Nachega J.B., Emergence of HIV Drug Resistance During First- and Second-Line Antiretroviral Therapy in Resource-Limited Settings. J Infect Dis. Oxford University Press; 2013;207: S49\u2013S56. 10.1093\/infdis\/jit107.","DOI":"10.1093\/infdis\/jit107"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0095","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1128\/AAC.48.1.172-175.2004","article-title":"Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-Infected patients switched to antiretroviral therapy without NNRTIs","volume":"48","author":"Joly","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0100","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/bioinformatics\/bts199","article-title":"Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data","volume":"28","author":"Kearse","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0105","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00002030-199610090-00007","article-title":"Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3 TC) versus zidovudine (ZDV) versus ZDV plus 3 TC in previously untreated patients","volume":"10","author":"Kuritzkes","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0110","doi-asserted-by":"crossref","first-page":"18580","DOI":"10.7448\/IAS.16.1.18580","article-title":"Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa","volume":"16","author":"Land","year":"2013","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0115","doi-asserted-by":"crossref","unstructured":"Larder B.A., Kemp S.D., Harrigan P.R., 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3 TC combination therapy. Science (80-). 269: 696 LP-699. Available: http:\/\/science.sciencemag.org\/content\/269\/5224\/696.Abstract.","DOI":"10.1126\/science.7542804"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0120","doi-asserted-by":"crossref","DOI":"10.3791\/51242","article-title":"An affordable HIV-1 drug resistance monitoring method for resource limited settings","author":"Manasa","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/135965359900400203","article-title":"Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study","volume":"4","author":"Masquelier","year":"1999","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0130","unstructured":"Report on the national HIV drug resistance prevention and assessment strategy: Zimbabwe, 2006\u20132008. 2008."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0135","unstructured":"National Medicine and Therapeutics Policy Advisory Committee (NMTPAC): Ministry of Health and Child Welfare. Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in Zimbabwe. Harare ; 2013."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0140","doi-asserted-by":"crossref","unstructured":"Rhee S.-Y., Gonzales M.J., Kantor R., Betts B.J., Ravela J., Shafer R.W., Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. Oxford, UK: Oxford University Press; 2003;31: 298\u2013303. Available: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC165547\/.","DOI":"10.1093\/nar\/gkg100"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0145","doi-asserted-by":"crossref","first-page":"e1001810","DOI":"10.1371\/journal.pmed.1001810","article-title":"Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis","volume":"12","author":"Rhee","year":"2015","journal-title":"PLoS Med. Publ. Lib. Sci."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0150","series-title":"HIV & TB Drug Resistance & Clinical Management Case Book","author":"Rossouw","year":"2013"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0155","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/ciu020","article-title":"Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels","volume":"58","author":"Santoro","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcv.2008.03.023","article-title":"The HIV-1 protease resistance mutation I50 L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts","volume":"42","author":"Sista","year":"2008","journal-title":"J. Clin. Virol. Elsevier"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0165","doi-asserted-by":"crossref","unstructured":"Thao V.P., Quang V.M., Day J.N., Chinh N.T., Shikuma C.M., Farrar J., et al., 2016. High prevalence of PI resistance in patients failing second-line ART in Vietnam. J Antimicrob Chemother. Oxford University Press; 71: 762\u2013774. 10.1093\/jac\/dkv385.","DOI":"10.1093\/jac\/dkv385"},{"key":"10.1016\/j.jviromet.2016.11.010_bib0170","unstructured":"UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. 2014."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0175","first-page":"77","article-title":"European recommendations for the clinical use of HIV drug resistance testing: 2011 update","volume":"13","author":"Vandamme","year":"2011","journal-title":"AIDS Rev."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0180","unstructured":"WHO, Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Switzerland, 2013."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0185","first-page":"642","article-title":"Special contribution 2014 update of the drug resistance mutations in HIV-1","author":"Wensing","year":"2014","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.jviromet.2016.11.010_bib0190","unstructured":"https:\/\/www.abbottmolecular.com\/products\/viroseq-hiv-1-genotyping-system.html (Accessed: October 2016) Internet."}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093416302890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093416302890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T23:43:53Z","timestamp":1657842233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093416302890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":38,"alternative-id":["S0166093416302890"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2016.11.010","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2016.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}